2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5230 The non-canonical conundrum: Response and survival impacts of targeting of non-canonical (NC) FLT3 mutations in acute myeloid leukemia (AML) in combination with intensive chemotherapy

Katherine Zhuo, MD, Kathryn (Katie) D. Russell, ARNP2, Carole Shaw3, Rutu Vyas, MPH4, Ruby Wacker5, Olivia Halle6, Suravi Raychaudhuri, MD7, Anna Halpern, MD8, Paul Hendrie, MD, PHD9, Raya Mawad, MD10, Cristina Maria Ghiuzeli, MD11, Bart L Scott, MD12, Ryan D. Cassaday, MD13, Soheil Meshinchi, MD, PhD14, Mary-Elizabeth Percival, MD15, Jacob Appelbaum, MD/PhD16
1 University of Washington, Seattle, Washington, United States
2 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 University of Washington, Seattle, Washington, United States
6 University of Washington, Seattle, Washington, United States
7 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
9 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
10 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
11 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
12 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
13 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
14 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
15 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
16 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

BACKGROUND
Mutations in FMS-like tyrosine kinase 3 (FLT3mut) occur in >30% of AML patients. Among FLT3mut, internal tandem duplication (ITD) is most common (~25%) and classified as intermediate risk in the absence of adverse risk markers according to the 2022 European LeukemiaNet (ELN) guidelines. A canonical tyrosine kinase domain (TKD) mutation occurs at D835 and is sensitive to midostaurin, but does not impact ELN 2022 risk. Additional NC FLT3mut, discovered by next generation sequencing (NGS), may be potentially activating, however sensitivity to FLT3i, and prognostic impacts are uncertain. Here we correlate FLT3 NGS results with outcomes, treatments, and FLT3i use to discern the clinical impacts of NC FLT3mut.

METHODS
We retrospectively identified patients ≥18 years of age with AML or other high-grade myeloid neoplasms (≥10% blasts in blood or marrow) evaluated at University of Washington/Fred Hutchinson Cancer Center between January 2016 – July 2026. FLT3 ITD, TKD (D835), or NC were identified via clinical NGS and/or polymerase chain reaction. Baseline features, including treatments, responses (based on ELN 2022) and overall survival (OS) were abstracted from medical records under an IRB approved protocol. Categorical variables were compared using the chi-squared statistic, and survival using log-rank analysis.

RESULTS

We identified 279 patients with FLT3 mut AML. The median age was 61 yrs (IQR 50, 70), 18.2% had secondary AML, and most had ECOG ≤ 2 (n = 242, 86.7%). ELN 2022 risk was favorable in 54 (19.4%), intermediate in 144 (51.6%), and adverse in 81 (29%). Single FLT3mut were ITD (n = 162, 58%), TKD (n = 51, 18%), and NC (n = 27, 10%). Multiple FLT3mut were identified in 39 patients (14%): (ITD/TKD in 17, ITD/NC in 13, TKD/NC in 8, ITD/TKD/NC in 1). Frequent NC FLT3mut were identified in the TKD1 region (A680V n = 8, N676K n = 8), TKD2 region (I836del n = 9) and extracellular domain (S451F n = 8). Overall, NC mutations were identified in 49 patients (17.6%). The most common co-mutated genes in all patients were NPM1 (47.7%), followed by DNMT3A (29.4%), TET2 (18.6%), NRAS (12.9%) and IDH2 (10.8%) and RUNX1 (10.8%).

Most patients initially received intensive chemotherapy (cladribine, cytarabine, and mitoxantrone [CLAG-M]), either alone (n = 70, 25%) or with gemtuzumab ozogamicin (GO, n = 51, 18%) or with FLT3i (n = 92, 33%; midostaurin = 49, sorafenib = 28, quizartinib = 15), while 23 received CLAG-M + GO + FLT3i.

Complete remission (CR) or CR with incomplete count recovery (CRi) was achieved in 215 patients (77%), of which 133 were MRDneg (62%). With median follow-up of 47.9 months, the median OS was 35.6 months (95% CI 23.5 – 54.6). Response rates and survival were similar across FLT3 mutation types. Among the subset of patients treated with CLAG-M±FLT3i, univariate analysis showed FLT3i addition increased rate of CR/CRi (OR 3.51, 95% CI 1.53-8.08) and improved OS (HR 0.35, 95% CI 0.22-0.55), even though more FLT3i-exposed patients had adverse risk disease. In multivariable regression (including ELN22 risk, age, treatment intensity and FLT3mut type), FLT3i usage remained associated with improved odds of CR (OR 3.43, 95% CI 1.72-6.85) and longer OS (HR 0.41, 95% CI 0.28–0.6). A stratified analysis showed OS benefit from FLT3i in all ELN risk groups for ITD (HR 0.49, 95% CI 0.29-0.81) and TKD mutations (HR 0.25, 95% CI 0.1-0.64).

Among NC FLT3muts, no difference in OS was noted between recurrent (n=14) and singleton (n=34) variants, so we evaluated them as a group. Univariate analysis did not confirm statistically significant benefits of FLT3i among NC patients (CR/CRi: OR = 4.27 p = 0.82, OS HR = 0.53, p = 0.156), and findings were similar across NC patient subsets, such as older/younger, intensive/less intensive chemotherapy, or co-mutation context. To account for differences in effect size among groups, we evaluated FLT3i benefit with an adjusted survival model: in the entire FLT3mut cohort, the adjusted HR was 0.42 (95% CI 0.29-0.61), but in NC patients, the adjusted HR was 0.84 (95% CI 0.34-2.11), suggesting less benefit.

CONCLUSION

In this large cohort, we observed no significant difference in OS by FLT3 mutation type. FLT3i exposure improved OS in patients with FLT3 ITD and TKD mutations, with less apparent benefit for FLT3 NC patients. FLT3 NC mutations warrant further large-scale studies to define enzymatic activity, sensitivity to FLT3i in vitro and in vivo, and optimal timing of FLT3i use.  

Katherine Zhuo, MD: No relevant conflicts of interest to declare.